- Home
- SSP vs FULC Comparison
SSP vs FULC Comparison
Compare SSP & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSP | FULC |
|---|---|---|
| Founded | 1878 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.2M | 468.1M |
| IPO Year | 1988 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SSP | FULC |
|---|---|---|
| Price | $4.71 | $12.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $5.50 | ★ $16.38 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,318,706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $1.36 | $2.32 |
| 52 Week High | $4.98 | $15.74 |
Technical Indicators
Market Signals| Indicator | SSP | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 58.12 |
| Support Level | $4.27 | $11.98 |
| Resistance Level | $4.98 | $13.26 |
| Average True Range (ATR) | 0.35 | 1.22 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 75.25 | 54.64 |
Price Performance
Historical ComparisonAbout SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.